REVB 1.44 ▲ 2.86% Live Trading Data - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Revelation Biosciences In...

    NASDAQ: REVB · Real-Time Price · USD
    1.44
    0.04 (2.86%)
    At close: Sep 26, 2025, 11:09 AM
    2.86%
    Bid 1.02
    Market Cap 2.45M
    Revenue (ttm) 26.96K
    Net Income (ttm) -8.46M
    EPS (ttm) 866.22
    PE Ratio (ttm) n/a
    Forward PE -0.76
    Analyst n/a
    Dividends n/a
    Ask 1.8
    Volume 112,767
    Avg. Volume (20D) 436,755
    Open 1.40
    Previous Close 1.40
    Day's Range 1.40 - 1.48
    52-Week Range 1.40 - 60.48
    Beta -0.04
    Ex-Dividend Date n/a

    About REVB

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol REVB
    Website n/a
    Full Company Profile
    2 weeks ago
    -19.03%
    Revelation Biosciences shares are trading lower af... Unlock content with Pro Subscription
    2 weeks ago
    -17.38%
    Revelation Biosciences shares are trading lower. The company announced safety and activity data for Phase 1 PRIME study.
    news image

    2 weeks ago · accessnewswire.com

    Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds

    SAN DIEGO, CA / ACCESS Newswire / September 11, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflamm...

    news image

    2 weeks ago · accessnewswire.com

    Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data

    - Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients - - Gemini could potentially revolutionize the treatment of acute and chronic inflammatory disease - D...

    news image

    2 weeks ago · accessnewswire.com

    Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data

    SAN DIEGO, CA / ACCESS Newswire / September 9, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company focused on rebalancing inflamma...

    news image

    2 weeks ago · accessnewswire.com

    Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study

    - Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients - - Gemini could potentially revolutionize the treatment of acute and chronic inflammatory disease - D...

    news image

    1 month ago · businesswire.com

    Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025

    SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on rebalancing inflammati...

    news image

    2 months ago · businesswire.com

    Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study

    SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company focused on rebalancing inflammation to op...

    news image

    2 months ago · businesswire.com

    Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025

    SAN DIEGO--(BUSINESS WIRE)---- $REVB #AKI--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), announced today that, on July 7, 2025, the Company will implement a 1-for-3 reve...

    Add to Watchlist